Intercept Pharmaceuticals Inc (NASDAQ:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), announced the appointment of Juan Carlos Lopez-Talavera, M.D., Ph.D. as Senior Vice President of Medical Affairs.
“Juan Carlos brings more than 20 years of industry and academic experience to Intercept and is a globally recognized hepatologist,” said David Shapiro, M.D., Chief Medical Officer. “We will benefit greatly from Juan Carlos’s considerable expertise in working with the medical community to enhance understanding of underserved liver diseases and strategies for improving patient care.”
Dr. Lopez-Talavera most recently served as Head of Hepatology R&D and Vice President of Medical Affairs at Abbvie, where he was responsible for all Medical Affairs activities supporting the global launch of Abbvie’s regimen for the treatment of Hepatitis C.
Before joining Abbvie, he held positions of increasing responsibility at Roche and Bristol-Myers Squibb, as well as academic positions at the Universidad Autonoma de Barcelona, the University of Pittsburgh School of Medicine, and Yale University School of Medicine.
“It is exciting to be joining Intercept at such a pivotal moment in the field of hepatology as the Company redefines the treatment of underserved liver diseases,” said Dr. Lopez-Talavera. “There is an urgent need for new therapies for these diseases and I’m looking forward to advancing Intercept’s innovative clinical program to help us better understand how to treat the millions of people across the globe living with PBC, NASH and other chronic liver diseases.” (Original Source)
Shares of Intercept Pharmaceuticals closed last Friday at $263.81 . ICPT has a 1-year high of $349.08 and a 1-year low of $128.50. The stock’s 50-day moving average is $263.80 and its 200-day moving average is $227.73.
On the ratings front, Intercept Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on June 2, Wedbush analyst Liana Moussatos reiterated a Buy rating on ICPT, with a price target of $493, which implies an upside of 86.9% from current levels. Separately, on May 19, BMO’s Jim Birchenough reiterated a Buy rating on the stock and has a price target of $515.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Liana Moussatos and Jim Birchenough have a total average return of 35.8% and 42.5% respectively. Moussatos has a success rate of 56.5% and is ranked #23 out of 3638 analysts, while Birchenough has a success rate of 67.3% and is ranked #10.
The street is mostly Bullish on ICPT stock. Out of 12 analysts who cover the stock, 9 suggest a Buy rating and 3 recommend to Hold the stock. The 12-month average price target assigned to the stock is $409.09, which represents a potential upside of 55.1% from where the stock is currently trading.
Intercept Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry.